Short Bowel Syndrome - Epidemiology Forecast - 2032

Key Highlights

• Total prevalent caese of home parenteral nutrition (HPN) in the 7MM was ~40,000 in 2022.
• In the 7MM, the maximum cases of prevalent cases of short bowel syndrome were reported in the United States, accounting for nearly 14,000 cases in 2022.
• Germany had the highest number of prevalent cases of short bowel syndrome among the EU4 and the UK, followed by the UK, whereas Spain had the lowest number of cases.
• In 2022, Japan accounted for roughly 850 cases in adults and 150 cases in pediatric population.

This “Short Bowel Syndrome (SBS) - Market Insights, Epidemiology and Market Forecast - 2032” report delivers an in-depth understanding of short bowel syndrome, historical and forecasted epidemiology as well as short bowel syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The short bowel syndrome market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM short bowel syndrome market size from 2019 to 2032. The report also covers current short bowel syndrome treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Short Bowel Syndrome Disease Understanding and Diagnosis

Short Bowel Syndrome Overview

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Consequently, individuals with short bowel syndrome often have a reduced ability to absorb nutrients such as fats, carbohydrates (sugars) vitamins, minerals, trace elements and fluids (malabsorption). The specific symptoms and severity of short bowel syndrome vary from one person to another. Diarrhea is common, often severe and can cause dehydration, which can even be life threatening. Short bowel syndrome can lead to malnutrition, unintended weight loss and additional symptoms may be due to the loss of essential vitamins and minerals. There is no cure, but the disorder usually can be treated effectively. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications.

Short Bowel Syndrome Diagnosis

A diagnosis of short bowel syndrome is made based upon a detailed patient history, a thorough clinical evaluation and a variety of specialized tests including laboratory tests and X-ray studies.

A health care provider diagnoses SBS based on a medical and family history, a physical exam, blood tests such as CBC, albumin, creatinine tests, and others. Fecal fat tests is also performed, which can show how well the small intestine is working. Imaging techniques may be used to assess individuals with short bowel syndrome. Such tests include plain abdominal X-rays to detect signs of obstruction or ileus (paralysis of intestinal muscles), computerized tomography (CT) scanning of the abdomen (abdominal CAT scan), magnetic resonance imaging (MRI) of the abdomen or an abdominal ultrasound. Upper GI series, also called a barium swallow, uses X-rays and fluoroscopy to help diagnose problems of the upper GI tract.

Further details related to diagnosis are provided in the report…

Short Bowel Syndrome Epidemiology

The short bowel syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by prevalent cases of home parenteral nutrition (HPN), diagnosed prevalent cases of short bowel syndrome, age-specific cases of SBS, gender-specific cases of SBS, etiology-specific cases in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032.

• In the 7MM, the highest prevalent cases of SBS were seen in the United States, followed by EU4 and the UK in 2022.
• Short bowel syndrome is more common in females as compared to males. In the United States, more than 67% of females are diagnosed with short bowel syndrome.
• In the United States, there were around 29% surgical complications and nearly 24% mesenteric infarction cases cause found in short bowel syndrome in 2022.
• In EU4 and the UK age-specific cases of short bowel syndrome, the highest number of cases accounting for were observed in adults compared with pedriatic.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of short bowel syndrome, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.
• A detailed review of the short bowel syndrome epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Short Bowel Syndrome (SBS) Report Insights

• Patient Population
• Patient population by gender, etiology, and age
• Country-wise Epidemiology Distribution

Short Bowel Syndrome (SBS) Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Short Bowel Syndrome Epidemiology Segmentation

Short Bowel Syndrome (SBS) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions Answered

Epidemiology Insights:

• What are the disease risk and burdens and of short bowel syndrome? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to short bowel syndrome?
• What is the historical and forecasted short bowel syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which age group is the largest contributor in patients affected with short bowel syndrome?
• What factors affect the increase in the patient number in later lines of short bowel syndrome therapy?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.